Compare NSP & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSP | SPRY |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 833.1M |
| IPO Year | 1996 | 2020 |
| Metric | NSP | SPRY |
|---|---|---|
| Price | $31.73 | $8.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $47.67 | $40.00 |
| AVG Volume (30 Days) | 816.6K | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,812,000,000.00 | $84,278,000.00 |
| Revenue This Year | $3.45 | $90.76 |
| Revenue Next Year | $6.95 | $81.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.51 | N/A |
| 52 Week Low | $18.57 | $6.66 |
| 52 Week High | $80.45 | $18.63 |
| Indicator | NSP | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 47.22 |
| Support Level | $31.00 | $8.05 |
| Resistance Level | $39.86 | $8.63 |
| Average True Range (ATR) | 1.75 | 0.37 |
| MACD | 0.47 | 0.05 |
| Stochastic Oscillator | 96.55 | 55.36 |
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.